I've run some numbers to see what the veterinary side of things could potentially be earning in the next couple of years while human trials are ongoing.
- The $10mill was raised giving 208,333,334 shares.
- From the OIS there are a total of 220,511 incidences of treatable cancer (with EBC-46) in Australia per year. The drug will only be available in Australia in the next couple of years so I'm limiting just to Aussie.
- Assuming in the first year (2011) 5% of the total of the above cases are treated with EBC-46, increasing by 10% increments of the total cases annually.
- Assuming there's about $300 profit per treatment (I believe this is ballpark figure)
Year 1 (5% cases treated) - EPS = $0.016 , Total Profit = $3,307,665
Year 2 (15% cases treated) - EPS = $0.032 , Total Profit = $6,615,330
Year 3 (25% cases treated) - EPS = $0.048 , Total Profit = $9,922,995
Say we use this and a conservative P/E = 5 (considering unlisted, high risk, etc) to estimate a market cap for the Veterinary side of the company we get:
Year 1 = $16,538,325
Year 2 = $33,076,650
Year 3 = $49,614,975
So any comments?
I think the veterinary market in Australia has great earning potential. Ecobiotics owns 84% of Qbiotics so this should also be taken into consideration.
- Forums
- ASX - General
- cure for cancer...you can invest
I've run some numbers to see what the veterinary side of things...
-
-
- There are more pages in this discussion • 298 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online